CT perfusion may help classify canine adrenal tumors preoperatively

A new American Journal of Veterinary Research study points to CT perfusion as a potentially useful tool for preoperative differentiation of canine pheochromocytomas from adrenocortical tumors, an imaging problem with real surgical consequences. According to the study abstract, the authors assessed CT perfusion-derived time to highest observed adrenal tissue enhancement, arterial blood flow, and the tumor-to-contralateral adrenal arterial blood flow ratio, then evaluated how those measures aligned with triple-phase CT findings and diagnostic performance. (ecvs.org)

That matters because adrenal tumor type can shape everything that follows, from referral conversations to anesthetic preparation. In dogs, pheochromocytomas arise from the adrenal medulla and are often clinically important not just because of catecholamine secretion, but because they can be locally invasive and technically difficult to remove. Merck’s veterinary reference notes that CT is already a key modality for confirming suspected adrenal masses and assessing spread, while older and newer veterinary imaging studies have shown CT can be valuable for identifying vascular invasion and supporting surgical planning. (merckvetmanual.com)

The new paper appears to extend a line of work from the same broader research group. A 2016 Veterinary Surgery study that included Kumiko Ishigaki and Chieko Ishikawa concluded that triple-phase helical CT could feasibly differentiate canine adrenal tumor types based on morphologic features, CT attenuation values, and intratumoral enhancement patterns. More recently, the group has also published CT perfusion work in other canine tumors, including prostate adenocarcinoma and hepatocellular carcinoma, suggesting they are building a broader veterinary evidence base for perfusion imaging rather than reporting a one-off experiment. (pubmed.ncbi.nlm.nih.gov)

Although the full AJVR article was not directly accessible in the search results, the available abstract and related conference material indicate the study focused on whether quantitative perfusion markers can separate pheochromocytomas from adrenocortical tumors more reliably than conventional descriptive imaging alone. A European College of Veterinary Surgeons abstract describing a retrospective case series from the same topic area reported promising diagnostic utility for preoperative CT perfusion in differentiating adrenomedullary from adrenocortical tumors. That conference report involved a small number of histopathologically classified lesions, which suggests the AJVR paper is likely still an early-stage evidence signal rather than a practice-changing definitive trial. (ecvs.org)

The broader literature helps explain why this approach is getting attention. Contrast-enhanced ultrasound has shown promise for adrenal tumor differentiation, with one study reporting strong diagnostic performance for mean transit time in distinguishing pheochromocytoma from adrenocortical tumors, but no modality has fully solved the problem. Other emerging approaches, including CT texture analysis, cytology, and even ^18F-FDOPA PET/CT, are also being explored for cases where conventional imaging and endocrine testing leave uncertainty. In that context, CT perfusion fits into a larger push toward more functional, quantitative imaging for adrenal cases. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, the practical value here is less about novelty and more about risk stratification. If clinicians can more confidently suspect pheochromocytoma before surgery, they can better prepare for hemodynamic instability, possible vascular involvement, and referral-level surgical complexity. Prior CT studies in dogs have reported high accuracy for detecting vascular invasion, and imaging reviews continue to frame CT as central to preoperative adrenal assessment. A perfusion-based add-on could improve confidence in cases where morphology is equivocal, especially at specialty centers already using advanced CT protocols. (pubmed.ncbi.nlm.nih.gov)

There are also clear limitations. CT perfusion requires specialized acquisition protocols, software, and expertise, and the available signals suggest small sample sizes remain an issue. That means widespread adoption in general practice is unlikely in the near term, and even in referral medicine, CT perfusion would probably serve as an adjunct rather than a replacement for triple-phase CT, endocrine testing, histopathology, or surgical judgment. That inference is consistent with the wider veterinary CT perfusion literature, which generally presents the technology as promising, but not standalone. (pubmed.ncbi.nlm.nih.gov)

What to watch: Watch for the full AJVR paper’s performance metrics, any proposed cutoff values, and whether outside groups replicate the findings in larger prospective cohorts. The bigger question for the field is whether CT perfusion will prove incremental enough over triple-phase CT and contrast-enhanced ultrasound to become part of routine adrenal workups at referral centers, or remain a niche research and advanced imaging tool. (pubmed.ncbi.nlm.nih.gov)